CalciMedica, Inc. (CALC) Stock Forecast
CALC analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 4 analysts
- Price target
- $38.00 average of analyst targets
- Upside to target
- +3,553.8% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.75
- 52-week range
- $1.04 – $33.70
CALC analyst ratings
4 analystsNumber of analysts at each rating.
CALC price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CALC earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.27 | −$1.80 | −$0.75 | −$2.60 | +51.0% | 2 |
| Current fiscal year (2026) | −$3.02 | −$3.95 | −$2.45 | −$9.85 | +69.4% | 3 |
| Next fiscal year (2027) | −$5.30 | −$10.60 | −$2.15 | −$3.02 | −75.7% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CALC revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 4 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 3 |
CALC EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CALC EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.72 | −$1.68 | −$1.98 | −$1.98 | −$1.27 | −25.7% | 1 up · 0 down |
| Current fiscal year (2026) | −$3.13 | −$3.13 | −$3.77 | −$3.30 | −$3.02 | −3.7% | 1 up · 1 down |
| Next fiscal year (2027) | −$9.78 | −$9.78 | −$5.72 | −$6.88 | −$5.30 | −45.8% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CALC earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CALC beat in 6 of 12.
What analysts expect from CALC
4 analysts cover CalciMedica; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $38.00, 3,553.8% above the latest close of $1.04. Analysts expect earnings of −$3.02 per share for 2026, +69.4% from a year earlier. For 2027 the average estimate is −$5.30 per share. CalciMedica beat the EPS estimate in 6 of the last 12 quarters.
Related: CALC income statement, CALC key metrics, CALC chart. See the CALC stock overview for the latest quote and news.
CALC forecast FAQ
What is CalciMedica's price target?
The average analyst price target for CalciMedica is $38.00, 3,553.8% above the latest close of $1.04.
Is CalciMedica a buy, hold or sell?
Of 4 analysts covering CalciMedica, 3 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is CalciMedica's EPS forecast?
Analysts forecast −$3.02 per share for 2026 (range −$3.95 to −$2.45); for 2027 the estimate is −$5.30.
When does CalciMedica report earnings?
CalciMedica is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.75.
Does CalciMedica usually beat earnings estimates?
CalciMedica reported EPS at or above the analyst estimate in 6 of the last 12 quarters.